SCHEMBL846131

SCHEMBL846131

CC(C)(C)c1ccc(CCC(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ NR1H4 Q96RI1 6/20 0.71
▸ EPHX2 P34913 1/20 0.71
▸ RXRA P19793 1/20 0.70
▸ RXRB P28702 1/20 0.70
▸ RXRG P48443 1/20 0.70
▸ FFAR1 O14842 4/20 0.59
▸ SLC13A5 Q86YT5 2/20 0.58
▸ KEAP1 Q14145 1/20 0.57
▸ ESRRG P62508 1/20 0.54
▸ NPSR1 Q6W5P4 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1453852 0.89 NR1H4 (0.73) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL10533225 0.87 NR1H4 (0.67) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL7407541 0.86 RXRA (0.58) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL19920076 0.86 NR1H4 (0.57) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL11387939 0.86 NR1H4 (0.55) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL10472979 0.85 NR1H4 (0.65) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL2953957 0.84 ALDH1A1 (0.59) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL861913 0.83 RXRA (0.55) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL13778182 0.83 NR1H4 (0.54) NR1H4EPHX2RXRARXRBRXRG
SCHEMBL69746 0.82 FFAR1 (0.81) FFAR1KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 — — WO claimed
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2025-05-20 — — US claimed
CN-117396590-A Perfume for improving relaxation state and evaluation method 奇华顿股份有限公司 2024-01-12 — — CN claimed
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2022-06-23 — — US claimed
US-11253596-B2 Phenylalkylcarboxylic acid delivery agents NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2022-02-22 — — US claimed
US-20200405863-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS NOVO NORDISK A/S (DK) 2020-12-31 — — US claimed
WO-2020210922-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11Β-HSD1) PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) 2020-10-22 — — WO claimed
EP-2114145-B1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECH INC (US) 2017-11-01 — — EP claimed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 — — US claimed
CN-106456662-A Compositions of pentosan polysulfate for oral administration and methods of use thereof 奥利金制药公司 2017-02-22 — — CN claimed
CN-105233294-A Phenylalkylcarboxylic acid delivery agent EMISPHERE TECH INC 2016-01-13 — — CN claimed
US-20120258911-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2012-10-11 — — US claimed
US-20110046050-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2011-02-24 — — US claimed
CN-101616583-A Phenylalkylcarboxylic acid delivery agents EMISPHERE TECH INC 2009-12-30 — — CN claimed
EP-2114145-A2 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS Emisphere Technologies, Inc. (US) 2009-11-11 — — EP claimed
WO-2008112368-A2 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2008-09-18 — — WO claimed
US-5183931-A Catalyzing with carboxylic acid medium in presence of palladium salt, metal persulfate, metal salt and tin salt PHILLIPS PETROLEUM COMPANY (US) 1993-02-02 — — US claimed
EP-0012942-B1 ELECTROLYTIC PROCESS FOR PRODUCING BENZALDEHYDES BASF Aktiengesellschaft (DE) 1982-01-27 — — EP claimed
EP-0012942-A2 Electrolytic process for producing benzaldehydes BASF Aktiengesellschaft (DE) 1980-07-09 — — EP claimed
WO-2025151884-A1 USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE PARSONS C LOWELL (US) 2025-07-17 — — WO disclosed
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2025-05-20 — — US disclosed
CN-114957174-B Alkyl substituted alpha-methylene-gamma-butyrolactone derivative and synthesis method thereof 华南理工大学 2024-06-21 — — CN disclosed
US-20230372297-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2023-11-23 — — US disclosed
EP-3688124-B1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME EXXONMOBIL CHEMICAL PATENTS INC (US) 2023-10-25 — — EP disclosed
WO-2023160582-A1 THIAZOLAMINE MBL INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川大学 2023-08-31 — — WO disclosed
CN-114891070-A Anthelmintic depsipeptide compounds 勃林格殷格翰动物保健美国公司 2022-08-12 — — CN disclosed
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2022-06-23 — — US disclosed
CN-107835818-B Anthelmintic depsipeptide compounds 勃林格殷格翰动物保健美国公司 2022-04-29 — — CN disclosed
US-11253596-B2 Phenylalkylcarboxylic acid delivery agents NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) 2022-02-22 — — US disclosed
CN-111777477-B Method for synthesizing succinic acid derivative or 3-aryl propionic acid 四川大学 2021-09-14 — — CN disclosed
US-20200405863-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS NOVO NORDISK A/S (DK) 2020-12-31 — — US disclosed
WO-2020210922-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11Β-HSD1) PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) 2020-10-22 — — WO disclosed
US-20200330435-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2020-10-22 — — US disclosed
CN-111777477-A Method for synthesizing succinic acid derivative or 3-aryl propionic acid 四川大学 2020-10-16 — — CN disclosed
CN-111592521-A Amino acid group S-carboxyl internal cyclic anhydride and functionalized poly-thioester and preparation method thereof 中国科学院长春应用化学研究所 2020-08-28 — — CN disclosed
EP-3688124-A1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME ExxonMobil Chemical Patents Inc. (US) 2020-08-05 — — EP disclosed
US-10711216-B2 Ester compounds, lubricating oil compositions containing same and processes for making same EXXONMOBIL CHEMICAL PATENTS INC. (US) 2020-07-14 — — US disclosed
CN-111386331-A Ester compound, lubricating oil composition containing same, and method for producing same 埃克森美孚化学专利公司 2020-07-07 — — CN disclosed
US-10456472-B2 Phenylalkylcarboxylic acid delivery agents EMISPHERE TECHNOLOGIES, INC. (US) 2019-10-29 — — US disclosed
US-20190100710-A1 Ester Compounds, Lubricating Oil Compositions Containing Same and Processes for Making Same EXXONMOBIL CHEMICAL PATENTS INC. 2019-04-04 — — US disclosed
WO-2019067061-A1 ESTER COMPOUNDS, LUBRICATING OIL COMPOSITIONS CONTAINING SAME AND PROCESSES FOR MAKING SAME EXXONMOBIL CHEMICAL PATENTS INC. (US) 2019-04-04 — — WO disclosed
US-20190038600-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES BOEHRINGER INGELHEIM INT (DE) 2019-02-07 — — US disclosed
US-20180194799-A1 BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-07-12 — — US disclosed
US-20180194799-A1 BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-07-12 — — US disclosed
CN-107669669-A novel glucagon receptor antagonist 症变治疗公司 2018-02-09 — — CN disclosed
EP-2114145-B1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECH INC (US) 2017-11-01 — — EP disclosed
EP-2114145-B1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECH INC (US) 2017-11-01 — — EP disclosed
WO-2017165676-A1 METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS PROTAGONIST THERAPEUTICS, INC. (US) 2017-09-28 — — WO disclosed
CN-101610995-B Glucagon receptor antagonists 症变治疗公司 2017-08-08 — — CN disclosed
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) 2017-07-06 — — US disclosed
CN-106456662-A Compositions of pentosan polysulfate for oral administration and methods of use thereof 奥利金制药公司 2017-02-22 — — CN disclosed
US-20160375135-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2016-12-29 — — US disclosed
US-20160375135-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2016-12-29 — — US disclosed
US-9517994-B2 Antibacterial agents: phloroglucinol derivatives RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2016-12-13 — — US disclosed
US-20160136133-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES BOEHRINGER INGELHEIM INT (DE) 2016-05-19 — — US disclosed
CN-105233294-A Phenylalkylcarboxylic acid delivery agent EMISPHERE TECH INC 2016-01-13 — — CN disclosed
US-20150011647-A1 ANTIBACTERIAL AGENTS: PHLOROGLUCINOL DERIVATIVES HOWARD HUGHES MEDICAL INSTITUTE 2015-01-08 — — US disclosed
EP-1888596-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2014-10-22 — — EP disclosed
US-20140296217-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-02 — — US disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 — — US disclosed
US-8772307-B2 Substituted spiro compounds and their use for producing pain-relief medicaments GRUENENTHAL GMBH (DE) 2014-07-08 — — US disclosed
US-8772307-B2 Substituted spiro compounds and their use for producing pain-relief medicaments GRUENENTHAL GMBH (DE) 2014-07-08 — — US disclosed
US-8530462-B2 Indole modulators of S1P receptors ALLERGAN, INC. (US) 2013-09-10 — — US disclosed
WO-2013103969-A1 ANTIBACTERIAL AGENTS: PHLOROGLUCINOL DERIVATIVES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2013-07-11 — — WO disclosed
US-8466295-B2 Thiophene derivatives as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-06-18 — — US disclosed
EP-1861357-B1 NOVEL COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORP (KR) 2013-04-24 — — EP disclosed
US-8410155-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 — — US disclosed
US-8410155-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-04-02 — — US disclosed
US-8394828-B2 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, NV (BE) 2013-03-12 — — US disclosed
US-8394828-B2 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, NV (BE) 2013-03-12 — — US disclosed
US-8394828-B2 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, NV (BE) 2013-03-12 — — US disclosed
US-20120309794-A1 COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS UNIVERSITÀ DI PISA (IT) 2012-12-06 — — US disclosed
US-20120309794-A1 COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS UNIVERSITÀ DI PISA (IT) 2012-12-06 — — US disclosed
US-20120270853-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-10-25 — — US disclosed
US-20120258911-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2012-10-11 — — US disclosed
US-20120258911-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2012-10-11 — — US disclosed
US-20120258911-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2012-10-11 — — US disclosed
US-8252830-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-08-28 — — US disclosed
US-20120129829-A1 NOVEL INDOLE MODULATORS OF S1P RECEPTORS ALLERGAN, INC. (US) 2012-05-24 — — US disclosed
US-8163749-B2 Six-membered heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-04-24 — — US disclosed
EP-1603883-B1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA NV (BE) 2012-03-28 — — EP disclosed
US-8071650-B2 Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea PACIFIC CORPORATION (KR) 2011-12-06 — — US disclosed
US-8071650-B2 Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea PACIFIC CORPORATION (KR) 2011-12-06 — — US disclosed
US-20110190364-A1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2011-08-04 — — US disclosed
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2011-08-04 — — US disclosed
US-20110183958-A1 AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. 2011-07-28 — — US disclosed
US-7960584-B2 3-(4-t-butyl-phenyl)-N-(4-methanesulfonylamino-benzyl)-2-methyl-acrylamide; pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane AMOREPACIFIC CORPORATION (KR) 2011-06-14 — — US disclosed
US-7951829-B2 Benzimidazole modulators of VR1 JANSSEN PHARMACEUTICA NV (BE) 2011-05-31 — — US disclosed
EP-2308848-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor Janssen Pharmaceutica NV (BE) 2011-04-13 — — EP disclosed
EP-2308848-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor Janssen Pharmaceutica NV (BE) 2011-04-13 — — EP disclosed
US-20110046050-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2011-02-24 — — US disclosed
US-20110046050-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2011-02-24 — — US disclosed
US-20110046050-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2011-02-24 — — US disclosed
US-20110028446-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2011-02-03 — — US disclosed
US-7858616-B2 Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-12-28 — — US disclosed
US-7858616-B2 Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-12-28 — — US disclosed
US-7842708-B2 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-11-30 — — US disclosed
EP-2021330-B1 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA NV (BE) 2010-09-22 — — EP disclosed
US-20100204211-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-12 — — US disclosed
US-7763657-B2 Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same AMOREPACIFIC CORPORATION (KR) 2010-07-27 — — US disclosed
US-7737154-B2 CRF receptor antagonists and methods relating thereto SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2010-06-15 — — US disclosed
US-7737154-B2 CRF receptor antagonists and methods relating thereto SMITHKLINE BEECHAM (CORK) LIMITED (IE) 2010-06-15 — — US disclosed
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS GENETIC TECHNOLOGIES LIMITED (AU) 2010-06-03 — — US disclosed
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-28 — — US disclosed
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-28 — — US disclosed
US-20100016316-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-21 — — US disclosed
US-20100016316-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-01-21 — — US disclosed
CN-101616583-A Phenylalkylcarboxylic acid delivery agents EMISPHERE TECH INC 2009-12-30 — — CN disclosed
US-7626039-B2 Arylpropionamide, arylacrylamide, ayrlpropynamide, or arylmethylurea analogs as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-01 — — US disclosed
EP-2114145-A2 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS Emisphere Technologies, Inc. (US) 2009-11-11 — — EP disclosed
US-20090253766-A1 THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 — — US disclosed
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 — — US disclosed
US-20090203676-A1 G-protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2009-08-13 — — US disclosed
US-20090197876-A1 INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-08-06 — — US disclosed
US-20090197876-A1 INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-08-06 — — US disclosed
US-20090181983-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL -MEYERS SQUIBB COMPANY 2009-07-16 — — US disclosed
US-20090181983-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL -MEYERS SQUIBB COMPANY 2009-07-16 — — US disclosed
US-7560480-B2 Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-07-14 — — US disclosed
US-7547703-B2 Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-06-16 — — US disclosed
US-7547703-B2 Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-06-16 — — US disclosed
US-20090118296-A1 Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase MERCK FROSST CANADA LTD. (CA) 2009-05-07 — — US disclosed
US-20090105258-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2009-04-23 — — US disclosed
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 — — US disclosed
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 — — US disclosed
EP-2021330-A2 BENZIMIDAZOLE MODULATORS OF VR1 Janssen Pharmaceutica, N.V. (BE) 2009-02-11 — — EP disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 — — US disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 — — US disclosed
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR CODD ELLEN 2008-12-04 — — US disclosed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 — — US disclosed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 — — US disclosed
US-20080234383-A1 Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same AMOREPACIFIC CORPORATION (KR) 2008-09-25 — — US disclosed
WO-2008112368-A2 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2008-09-18 — — WO disclosed
WO-2008112368-A2 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS EMISPHERE TECHNOLOGIES, INC. (US) 2008-09-18 — — WO disclosed
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB CO. 2008-07-03 — — US disclosed
EP-1303483-B1 NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME PACIFIC CORP (KR) 2008-04-23 — — EP disclosed
US-20080064687-A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same SUH YOUNG G 2008-03-13 — — US disclosed
US-20080064687-A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same SUH YOUNG G 2008-03-13 — — US disclosed
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto NEUROCRINE BIOSCIENCES, INC. 2007-12-13 — — US disclosed
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto NEUROCRINE BIOSCIENCES, INC. 2007-12-13 — — US disclosed
EP-1863756-A1 BIARYL DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2007-12-12 — — EP disclosed
EP-1861357-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Amorepacific Corporation (KR) 2007-12-05 — — EP disclosed
EP-1861358-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Amorepacific Corporation (KR) 2007-12-05 — — EP disclosed
WO-2007130780-A2 BENZIMIDAZOLE MODULATORS OF VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-15 — — WO disclosed
US-20070259936-A1 Benzimidazole Modulators of VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-08 — — US disclosed
US-7285563-B2 Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2007-10-23 — — US disclosed
US-20070191371-A1 HETEROCYCLIC MODULATORS OF PPAR KALYPSYS, INC. (US) 2007-08-16 — — US disclosed
US-7176231-B2 Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-02-13 — — US disclosed
US-7169936-B2 Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-30 — — US disclosed
US-7169936-B2 Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2007-01-30 — — US disclosed
US-20070004757-A1 INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS ROTH GERALD J 2007-01-04 — — US disclosed
US-20070004757-A1 INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS ROTH GERALD J 2007-01-04 — — US disclosed
US-20060223837-A1 Biaryl derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA, N.V. (BE) 2006-10-05 — — US disclosed
WO-2006101318-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2006-09-28 — — WO disclosed
WO-2006101321-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2006-09-28 — — WO disclosed
WO-2006102645-A1 BIARYL DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-09-28 — — WO disclosed
WO-2006098554-A1 NOVEL COMPOUNDS, ISOMER THEREOF OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2006-09-21 — — WO disclosed
EP-1603883-A2 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2005-12-14 — — EP disclosed
EP-1098891-B1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA GMBH (DE) 2005-08-10 — — EP disclosed
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2005-05-19 — — US disclosed
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor JANSSEN PHARMACEUTICA N.V. (BE) 2004-09-30 — — US disclosed
WO-2004069792-A2 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR JANSSEN PHARMACEUTICA N.V. (US) 2004-08-19 — — WO disclosed
CN-1144797-C Polycyclic thiazolidin-2-ylidene amines, method for production and use thereof as medicaments ���ĵ�˹ҩ��¹����޹�˾ 2004-04-07 — — CN disclosed
EP-1157047-B1 LIGANDS AND CATALYSTS FOR PRODUCING ELASTOMERIC PROPYLENE POLYMERS BP CORP NORTH AMERICA INC (US) 2003-04-23 — — EP disclosed
US-6479424-B1 FOR PRODUCING OLEFIN POLYMERS AND ESPECIALLY ELASTOMERIC PROPYLENE POLYMERS BP CORPORATION NORTH AMERICA INC. 2002-11-12 — — US disclosed
US-20020137967-A1 PROCESS FOR THE PREPARATION OF A CARBOXYLIC ACID COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH 2002-09-26 — — US disclosed
US-6444844-B1 Process for the preparation of a carboxylic acid COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2002-09-03 — — US disclosed
EP-1157047-A1 LIGANDS AND CATALYSTS FOR PRODUCING ELASTOMERIC PROPYLENE POLYMERS BP Corporation North America Inc. (US) 2001-11-28 — — EP disclosed
CN-1309653-A Polycyclic thiazolidin-2-ylidene amines, method for production and use thereof as medicaments AVENTIS PHARMA GMBH (DE) 2001-08-22 — — CN disclosed
EP-1098891-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS Aventis Pharma Deutschland GmbH (DE) 2001-05-16 — — EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
US-6159996-A Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-12-12 — — US disclosed
US-6103688-A TERT-BUTYL SUBSTITUTED INDAN DERIVATIVES FIRMENICH SA (CH) 2000-08-15 — — US disclosed
WO-2000035975-A1 LIGANDS AND CATALYSTS FOR PRODUCING ELASTOMERIC PROPYLENE POLYMERS BP CORPORATION NORTH AMERICA INC. (US) 2000-06-22 — — WO disclosed
WO-2000004006-A1 POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-27 — — WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed
EP-0721442-B1 OXIDATION OF ALKYLAROMATIC COMPOUNDS SOLVAY INTEROX LTD (GB) 1998-03-11 — — EP disclosed
US-5705705-A Oxidation of alkylaromatic compounds SOLVAY INTEROX LIMITED (GB) 1998-01-06 — — US disclosed
EP-0721442-A1 OXIDATION OF ALKYLAROMATIC COMPOUNDS SOLVAY INTEROX LIMITED (GB) 1996-07-17 — — EP disclosed
WO-1995009139-A1 OXIDATION OF ALKYLAROMATIC COMPOUNDS SOLVAY INTEROX LIMITED (GB) 1995-04-06 — — WO disclosed
US-5338726-A Hypotensive agents, antiulcer agents ABBOTT LABORATORIES (US) 1994-08-16 — — US disclosed
EP-0569487-A4 — — 1994-04-27 — — EP disclosed
EP-0580231-A1 Process for the preparation of 4-tert-butylbenzaldehyde IMI (TAMI) INSTITUTE FOR RESEARCH & DEVELOPMENT LTD. (IL) 1994-01-26 — — EP disclosed
US-5280001-A Palladium salt, metal persulfate, tin and other metal salt in carboxylic acid PHILLIPS PETROLEUM COMPANY (US) 1994-01-18 — — US disclosed
EP-0569487-A1 ENDOTHELIN CONVERTING ENZYME INHIBITORS ABBOTT LABORATORIES (US) 1993-11-18 — — EP disclosed
US-5183931-A Catalyzing with carboxylic acid medium in presence of palladium salt, metal persulfate, metal salt and tin salt PHILLIPS PETROLEUM COMPANY (US) 1993-02-02 — — US disclosed
WO-1992013545-A1 ENDOTHELIN CONVERTING ENZYME INHIBITORS ABBOTT LABORATORIES (US) 1992-08-20 — — WO disclosed
US-5128448-A Peptide hormones HOFFMAN-LA ROCHE INC. (US) 1992-07-07 — — US disclosed
EP-0253501-A2 N-disubstituted cycloalkylmethyl amines useful as fungicides IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-01-20 — — EP disclosed
EP-0072914-B1 PROCESS FOR THE PRODUCTION OF ALKYL-SUBSTITUTED BENZALDEHYDES BASF Aktiengesellschaft (DE) 1984-10-31 — — EP disclosed
EP-0072914-A1 Process for the production of alkyl-substituted benzaldehydes BASF Aktiengesellschaft (DE) 1983-03-02 — — EP disclosed
EP-0012942-B1 ELECTROLYTIC PROCESS FOR PRODUCING BENZALDEHYDES BASF Aktiengesellschaft (DE) 1982-01-27 — — EP disclosed
US-4245099-A ANTIINFLAMMATORY, ANALGESIC, DIURETIC, ANTIPYRETIC AND HYPOTENSIVE AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 1981-01-13 — — US disclosed
EP-0012942-A2 Electrolytic process for producing benzaldehydes BASF Aktiengesellschaft (DE) 1980-07-09 — — EP disclosed
EP-0012942-A2 Electrolytic process for producing benzaldehydes BASF Aktiengesellschaft (DE) 1980-07-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (48 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190364-A1 BENZIMIDAZOLE MODULATORS OF VR1 VRK1, VRK2, VIL1 NR1H4 465/4885EPHX2 4744/4885RXRA 1563/4885
US-20120270853-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 NR1H4 3166/4885EPHX2 396/4885RXRA 2765/4885
US-20090118296-A1 Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase SCD, SCD5, SREBF1 NR1H4 233/4885EPHX2 1001/4885RXRA 1073/4885
US-20100204211-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES MMP1, COL1A1, FOXM1 NR1H4 117/4885EPHX2 3118/4885RXRA 353/4885
US-20090105258-A1 NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME TRPV1, TRPA1, VIPR1 NR1H4 221/4885EPHX2 4174/4885RXRA 1292/4885
US-20070191371-A1 HETEROCYCLIC MODULATORS OF PPAR PPARG, PPARD, PPARA NR1H4 47/4885EPHX2 2803/4885RXRA 14/4885
US-20080234383-A1 Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same TRPV1, TRPA1, TRPV5 NR1H4 233/4885EPHX2 3068/4885RXRA 1486/4885
US-20120129829-A1 NOVEL INDOLE MODULATORS OF S1P RECEPTORS S1PR1, S1PR3, S1PR2 NR1H4 564/4885EPHX2 2467/4885RXRA 2166/4885
US-20070004757-A1 INDOLINE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS KDR, FLT1, EGFR NR1H4 563/4885EPHX2 3853/4885RXRA 2639/4885
US-20080161373-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 NR1H4 3166/4885EPHX2 396/4885RXRA 2765/4885
US-20200405863-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS PGF, LIPA, PDGFA NR1H4 677/4885EPHX2 522/4885RXRA 1277/4885
US-20070287705-A1 Crf Receptor Antagonists and Methods Relating Thereto CRHR1, CRHR2, CRH NR1H4 181/4885EPHX2 262/4885RXRA 1146/4885
US-20200330435-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES MMP1, COL1A1, FOXM1 NR1H4 117/4885EPHX2 3118/4885RXRA 353/4885
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) HSD11B1, HSD11B2, CYP11B1 NR1H4 778/4885EPHX2 1291/4885RXRA 3333/4885
US-20100016316-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS F12, TFPI, F11 NR1H4 2447/4885EPHX2 404/4885RXRA 1619/4885
US-20100137294-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS PPP1R10, TASP1, PPP5C NR1H4 4882/4885EPHX2 4469/4885RXRA 4583/4885
US-20180194799-A1 BETUIN DERIVATIVES FOR PREVENTING OR TREATING HIV INFECTIONS BET1, PGGT1B, RABGGTB NR1H4 1009/4885EPHX2 3545/4885RXRA 2165/4885
US-20120309794-A1 COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS LDHA, LDHB, DLD NR1H4 3296/4885EPHX2 737/4885RXRA 3617/4885
US-20070259936-A1 Benzimidazole Modulators of VR1 VRK1, VRK2, VIL1 NR1H4 465/4885EPHX2 4744/4885RXRA 1563/4885
US-20160136133-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES MMP1, COL1A1, FOXM1 NR1H4 117/4885EPHX2 3118/4885RXRA 353/4885
US-20230372297-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES MMP1, COL1A1, SMAD3 NR1H4 88/4885EPHX2 3021/4885RXRA 224/4885
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders INA, SCN1A, SI NR1H4 1192/4885EPHX2 4251/4885RXRA 1895/4885
US-20080064687-A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same TRPV1, TRPA1, TAS2R5 NR1H4 640/4885EPHX2 3840/4885RXRA 2865/4885
US-20110183958-A1 AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE SCD, SCD5, FADS2 NR1H4 880/4885EPHX2 2736/4885RXRA 3330/4885
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain ARRB1, OPRL1, CNR1 NR1H4 163/4885EPHX2 1878/4885RXRA 471/4885
US-10456472-B2 Phenylalkylcarboxylic acid delivery agents PGF, LIPA, PDGFA NR1H4 677/4885EPHX2 522/4885RXRA 1277/4885
US-20110046050-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS PGF, LIPA, PDGFA NR1H4 677/4885EPHX2 522/4885RXRA 1277/4885
US-20150011647-A1 ANTIBACTERIAL AGENTS: PHLOROGLUCINOL DERIVATIVES BET1, MRPL21, PHF6 NR1H4 2745/4885EPHX2 4619/4885RXRA 4446/4885
US-20140296217-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES MMP1, COL1A1, FOXM1 NR1H4 117/4885EPHX2 3118/4885RXRA 353/4885
US-20090253766-A1 THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS TFPI, F12, F11 NR1H4 3404/4885EPHX2 1466/4885RXRA 3697/4885
US-10711216-B2 Ester compounds, lubricating oil compositions containing same and processes for making same ELOVL1, NOTUM, ELOVL5 NR1H4 1131/4885EPHX2 154/4885RXRA 875/4885
US-20020137967-A1 PROCESS FOR THE PREPARATION OF A CARBOXYLIC ACID ADH5, ADH1C, ADH1A NR1H4 28/4885EPHX2 1108/4885RXRA 403/4885
US-20190038600-A1 MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES MMP1, COL1A1, IDO1 NR1H4 670/4885EPHX2 2570/4885RXRA 300/4885
US-20040192728-A1 Quinoline-derived amide modulators of vanilloid VR1 receptor TRPV1, OPRL1, TRPV2 NR1H4 414/4885EPHX2 3722/4885RXRA 731/4885
US-11253596-B2 Phenylalkylcarboxylic acid delivery agents PGF, LIPA, PDGFA NR1H4 677/4885EPHX2 522/4885RXRA 1277/4885
US-20110190344-A1 BENZIMIDAZOLE MODULATORS OF VR1 VRK1, VRK2, VIL1 NR1H4 465/4885EPHX2 4744/4885RXRA 1563/4885
US-20060223837-A1 Biaryl derived amide modulators of vanilloid VR1 receptor TRPV1, TRPV2, CNR1 NR1H4 138/4885EPHX2 2383/4885RXRA 755/4885
US-20170189443-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS SI, SLC20A1, SLC20A2 NR1H4 1587/4885EPHX2 1952/4885RXRA 4418/4885
US-20090181983-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS TFPI, F11, F12 NR1H4 1633/4885EPHX2 712/4885RXRA 3207/4885
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) HSD11B1, HSD11B2, HSD17B1 NR1H4 744/4885EPHX2 1170/4885RXRA 3014/4885
US-20090203676-A1 G-protein Coupled Receptor Agonists GPR119, GCGR, GPBAR1 NR1H4 77/4885EPHX2 1994/4885RXRA 322/4885
US-20160375135-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS PGF, LIPA, PDGFA NR1H4 677/4885EPHX2 522/4885RXRA 1277/4885
US-20090197876-A1 INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS KDR, FLT1, ERBB2 NR1H4 491/4885EPHX2 3648/4885RXRA 2417/4885
US-20080300236-A1 QUINOLINE-DERIVED AMIDE MODULATORS OF VANILLOID VR1 RECEPTOR TRPV1, OPRL1, TRPV2 NR1H4 414/4885EPHX2 3722/4885RXRA 731/4885
US-20190100710-A1 Ester Compounds, Lubricating Oil Compositions Containing Same and Processes for Making Same ELOVL1, NOTUM, ELOVL5 NR1H4 1131/4885EPHX2 154/4885RXRA 875/4885
US-20120258911-A1 PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS PGF, LIPA, PDGFA NR1H4 677/4885EPHX2 522/4885RXRA 1277/4885
US-20100022506-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 NR1H4 3166/4885EPHX2 396/4885RXRA 2765/4885
US-20110028446-A1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS TFPI, F11, F12 NR1H4 3166/4885EPHX2 396/4885RXRA 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback